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S U M M A R Y
Objectives: Visceral leishmaniasis (VL) is re-emerging in endemic areas. The epidemiological, clinical,
laboratory, and treatment outcome characteristics in a large cohort of VL patients is described herein.
Methods: The cases of 67 VL patients (57% male, mean age 56 years) treated in two Greek hospitals over
the last 7 years were identiﬁed and evaluated retrospectively.
Results: Forty-six percent of patients reported contact with animals. Seventeen patients (25%) were
immunocompromised, and 22% were co-infected with another pathogen. Sixty-four percent of patients
had fever, 57% had weakness, 37% had sweats, 21% had weight loss, and 13% had a dry cough, while 6%
developed haemophagocytic syndrome. The median duration of symptoms was 28 days. Fifty-eight
percent of patients had splenomegaly, 49% had hepatomegaly, and 36% had lymphadenopathy. The
diagnosis was established by positive PCR in peripheral blood (73%) and/or bone marrow specimens
(34%). Sixty-one patients (91%) received liposomal amphotericin (L-AMB). Six patients (10%) did not
respond or relapsed but were eventually cured after a second cycle of L-AMB. During a 6-month follow-
up, the overall mortality was 9%, although none of these deaths was attributed to VL.
Conclusions: VL is still a common disease in endemic areas, affecting immunocompetent and
immunocompromised patients. Its diagnosis is challenging, and molecular techniques are valuable
and helpful tools to achieve this. Treatment with L-AMB is safe and very effective.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Visceral leishmaniasis (VL) is an endemic and potentially life-
threatening disease in the tropics, subtropics, and Mediterranean
basin, including Greece. It is characterized by a broad range of
clinical and laboratory ﬁndings, such as fever, cachexia, hepatos-
plenomegaly, pancytopenia, hypergammaglobulinemia, and
hypoalbuminemia.1
Leishmaniasis is a mandatory notiﬁable disease in Greece.2
Leishmania infantum is the species responsible, while the most
common vectors are Phlebotomus neglectus, Phlebotomus tobbi, and
Phlebotomus perﬁliewi.3,4 Nevertheless, the true prevalence of VL is* Corresponding author. Tel.: +30 241 350 2285; fax: +30 241 350 1557.
E-mail address: georgedalekos@gmail.com (G.N. Dalekos).
http://dx.doi.org/10.1016/j.ijid.2015.02.021
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).probably underestimated, as infectious diseases are generally
under-reported in many countries, including Greece.5,6
Data on VL in Greece are scarce. Therefore, the aim of this study
was to report the epidemiological and clinical characteristics, risk
factors, diagnostic tools, treatment, and outcome of VL among
patients treated in two tertiary care Greek hospitals during the last
7 years.2,3,7–9
2. Patients and methods
All adult patients (age >14 years) with well-established VL
diagnosed at the Department of Medicine of the University General
Hospital of Larissa, and the Infectious Diseases Unit of the
Pathophysiology Department of the General Hospital of Athens
‘‘Laikon’’ from January 1, 2007 to December 31, 2013, were
evaluated. The patients’ electronic records/written charts wereciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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laboratory parameters, treatment outcome, and the mortality rate
at 24 weeks after diagnosis. The clinical manifestations and
potentially concurrent infections were also recorded.
An index patient was deﬁned according to international criteria
as a conﬁrmed VL case in the presence of clinical and laboratory
manifestations compatible with VL (i.e., two or more of persistent
fever >38 8C, hepatosplenomegaly, substantial weight loss, anae-
mia, leukopenia, polyclonal hypergammaglobulinemia, or lymph
node enlargement), along with a positive result for two of the
following three tests: serology (immunoﬂuorescence antibody
test), demonstration of parasite by smear in tissue samples (i.e.,
bone marrow smear, lymph node), or molecular techniques.1,10
Regarding molecular techniques, DNA extraction was per-
formed from 2 ml of blood or 1 ml of bone marrow, which was
suspended in 1 ml phosphate buffered saline (PBS) and layered
over Biocoll Separating Solution (Biochrom, Germany). After
centrifugation at 1800 rpm for 30 min, the interface was collected
and suspended in 8 ml of PBS. The suspension was centrifuged for
10 min at 2000 rpm and the supernatant was discarded. The pellet
was re-suspended in 0.2 ml of PBS. DNA extraction was then
performed using the QIAamp DNA Mini Kit (Qiagen, Germany),
following the manufacturer’s instructions. The DNA was eluted in
0.1 ml of buffer AE. A simple PCR reaction amplifying a fragment of
the SSU rRNA gene of Leishmania was used for detection, as
described previously.11 For Leishmania species identiﬁcation,
another previously described PCR method was also available.12
The patient was considered as immunosuppressed when there
was a history of malignant disease (haematological malignancy or
solid tumour) or a history of inherited or acquired immunodeﬁcien-
cy (e.g., splenectomy, HIV infection) or was under treatment with
immunosuppressive agents (e.g., corticosteroids, azathioprine,
methotrexate, and chemotherapeutic or biological agents). With
regard to corticosteroids, immunosuppression was considered if the
patient had received a dose of 5 mg of prednisone or equivalent,
every day, for at least the last 30 days. Anaemia was deﬁned when
haemoglobin was <12 g/dl in females and <13 g/dl in males.
Leukopenia and neutropenia were deﬁned when leukocyte and
neutrophil counts were less than 4  109/l and 1  109/l, respec-
tively. Thrombocytopenia was deﬁned when the platelet count was
less than 140  109/l. Levels of aspartate aminotransferase (AST),
alanine aminotransferase (ALT), C-reactive protein, albumin, and
gamma-globulins, and the erythrocyte sedimentation rate (ESR),
were determined using standard techniques.11
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Figure 1. Distribution of patients with visThe treatment schedule for liposomal amphotericin (L-AMB)
was administered according to the US Food and Drug Administra-
tion (FDA)-approved regimen for immunocompetent (3.0 mg/kg
on days 1 to 5, 14, and 21) and immunosuppressed patients
(3–5 mg/kg daily or intermittently for 10 doses (days 1–5, 10, 17,
24, 31, and 38) up to a total dose of 40–60 mg/kg).
Clinical response was assessed at the completion of treatment
and was deﬁned as cure (defervescence, restoration of laboratory
parameters, or signiﬁcant reduction in spleen size) or failure
(persistent or worsening of clinical and laboratory ﬁndings).
Relapse was deﬁned as the reappearance of signs and symptoms of
the disease within 6 months, in association with the identiﬁcation
of the parasite in a bone marrow smear, after initial successful
treatment.
The study was approved by the institutional review boards of
the two tertiary medical centres. All participants gave their
informed consent.
3. Results
Over the 7-year study period, 67 patients were identiﬁed with
well-established VL (56 in Larissa and 11 in the Athens medical
centre); their mean  SD age was 56.1  19.5 years and 38 were
males. The age distribution of the patients is shown in Figure 1. The
main clinical, physical, and laboratory ﬁndings of the patients are
shown in Table 1. Forty-four patients (66%) were living in rural areas
and 31 (46%) had been in frequent contact with animals (strays or
domestic dogs). At diagnosis, 17 patients (25%) were considered
immunocompromised; seven of them were under immunosuppres-
sion with corticosteroids, azathioprine, methotrexate, or anti-tumour
necrosis factor regimens due to autoimmune rheumatic diseases,
seven had an active underlying malignancy, and one patient each had
a history of splenectomy, hypogammaglobulinemia, and HIV infec-
tion. Moreover, nine patients (13%) suffered from diabetes mellitus.
The median duration of symptoms at diagnosis was 28 days
(range 1–240 days). Overall, 56 patients (84%) reported low-grade
fever, whereas 43 (64%) had a fever >38 8C. Thirty-eight patients
(57%) reported weakness, 14 (21%) loss of weight, and nine (13%) a
dry cough. Of interest, one patient presented only with fever and a
single intranasal bleeding lesion and two patients presented with
prolonged fever and neurological symptoms (acute polyradiculitis
and sensory-motor axonal neuropathy, respectively). Two patients
were recorded as asymptomatic, as the ﬁrst patient had only
splenomegaly and the second had enlarged inguinal lymph nodes.13
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Table 1
Clinical and laboratory characteristics of the 67 patients with visceral leishmaniasis
Characteristic No. (%) of patients
Clinical symptoms
Fever 43 (64)
Weakness 38 (57)
Sweats 25 (37)
Rigors 15 (22)
Loss of weight 14 (21)
Cough 9 (13)
Abdominal pain 8 (12)
Rasha 7 (10)
Headache 7 (10)
Bleeding 3 (4)
Diarrhoea 2 (3)
Neurological symptomsb 2 (3)
Physical ﬁndings
Splenomegaly 39 (58)
Hepatomegaly 33 (49)
Lymphadenopathy 24 (36)
Ascites 3 (4)
Peripheral oedema 2 (3)
Hyperpigmentation 1 (1)
Laboratory ﬁndings
Elevated inﬂammation markersc 54 (81)
Complete blood count
Anaemia 49 (73)
Thrombocytopenia 29 (43)
Leukopenia/neutropenia 27 (40)/12 (18)
Pancytopenia 23 (34)
Polyclonal hyperglobulinemia 40 (60)
Elevated transaminases 28 (42)
Low serum albumin 25 (37)
Microscopic haematuria 18 (27)
Positive non-organ speciﬁc autoantibodies 15 (22)
Low complement level 10 (15)
Positive rheumatoid factor 5 (7)
DIC 3 (4)
Cryoglobulinemia 1 (1)
DIC, disseminated intravascular coagulation.
a Haemorrhagic (n = 5), erythema nodosum (n = 1), urticaria (n = 1).
b Acute polyradiculitis (n = 1), sensory-motor axonal neuropathy (n = 1).
c Increased C-reactive protein and/or erythrocyte sedimentation rate.
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from other infections (co-infection), including ﬁve patients with a
well-established second zoonosis (brucellosis in three and Q-fever
in two), two patients each with lower respiratory infection, urinary
tract infection, primary bacteraemia, and intra-abdominal infec-
tion, as well as one patient each with osteomyelitis and bacterial
meningitis. Of note, four patients (6%) developed haemophagocytic
syndrome (HS) with a high fever, pancytopenia, splenomegaly,
haemophagocytosis in bone marrow, hypertriglyceridemia, and
high serum ferritin levels (range 636–23 782 mg/dl). Physical
examination revealed the presence of splenomegaly (39/67,
58.2%), hepatomegaly (33/67, 49.3%), and lymphadenopathy (24/
67, 35.8%).
In the majority of cases, the diagnosis was conﬁrmed by
positive PCR speciﬁc for Leishmania species in peripheral blood
(49 out of 54 patients tested, 91%) and/or bone marrow specimens
(23 out of 32 patients tested, 72%). In all patients with VL for whom
speciﬁcation of the parasite was requested, L. infantum was
exclusively identiﬁed. Furthermore, the diagnosis was established
by direct microscopy on bone marrow smears in 26 out of
48 patients tested (54%) and positive serology by immunoﬂuores-
cence in 15 out of 37 patients tested (41%).
Sixty-one patients (91%) received L-AMB (total dose 21 mg/kg
for the immunocompetent and 40 mg/kg for the immunocompro-
mised patients). Treatment side effects such as rigors, retrosternal
pain, dyspnoea, rash, and deterioration in renal function developed
in 12 patients (20%). Interestingly, one patient developed drug-
related myocarditis with a very low ejection fraction and acutepulmonary oedema that were reversed after L-AMB withdrawal.
Another patient experienced a tumour lysis-like syndrome during
treatment, with a transient deterioration in renal function and a
parallel elevation of uric acid levels without any other metabolic or
electrolyte disturbances. Consequently, due to serious side effects
under treatment with L-AMB, three patients were treated with
pentamidine (4 mg/kg every other day for up to 15 doses) due to
the lack of any other alternative drug regimen for VL in the study
hospitals (i.e. pentavalent antimonial drugs, paromomycin, or
miltefosine). Unfortunately, one of these patients developed renal
impairment and irreversible insulin-dependent diabetes mellitus.
Six (10%) patients in total did not respond to treatment or
relapsed within 6 months (two of them from the immunocompro-
mised group). All six of these patients received a second cycle of
L-AMB and were eventually cured. Following therapy, ﬁve
immunocompromised patients were given secondary prophylaxis
with intermittent administration of L-AMB (3 mg/kg every 21 days)
to prevent relapses due to the underlying disease (duration range
1–2.5 years). One of them – a patient with underlying myelodys-
plastic syndrome – relapsed 10 months after the initial diagnosis,
with a parallel transformation to acute myelogenous leukaemia,
and died a few days later. Of note, ﬁve patients did not receive any
treatment: three refused to be treated and two died of their
underlying malignant disease before the initiation of treatment.
One patient was lost to follow-up. Overall, six patients (9%) died
during a 6-month follow-up period (crude mortality) due to
bacterial infections (four patients) and underlying malignancy
(two patients). Interestingly, there was no signiﬁcant difference
regarding the demographic, clinical, laboratory, and treatment
outcome characteristics between immunocompetent and immu-
nocompromised patients in this study (Table 2).
4. Discussion
It was found that the disease burden of VL still carries a notable
morbidity in Greece, a Mediterranean country endemic for VL. A
remarkable proportion of patients were immunocompromised. Co-
infection with other pathogens was also common. In the majority
of cases (85%), the diagnosis of VL was established using molecular
techniques. Treatment with L-AMB was safe and effective.
Molecular-based diagnostic methods are indeed highly sensi-
tive and speciﬁc assays for the detection of Leishmania DNA13 and
are considered the cornerstone of the clinical algorithm for the
primary diagnosis of VL,10,14 especially in the case of HIV co-
infection.10,13,14 A lack of detailed standardization and global
homogenization and validation, together with the reduced
speciﬁcity in endemic areas, are the main disadvantages of these
useful diagnostic tools,15 whereas PCR positivity does not
distinguish asymptomatic infection from true active disease. The
deﬁnitive diagnosis of VL requires the demonstration of parasites
by smear in affected organ tissues, although serological tests such
as the indirect ﬂuorescent antibody test and detection of rK-39
antigen are also useful diagnostic tools. Unfortunately, due to the
retrospective design of this study, the detection of rK-39 antigen
was not available, although this method is quite cheap and has
high sensitivity and speciﬁcity (>98%).16
Recent reports have demonstrated a post-war re-emergence
and a current increasing incidence of VL in Greece following the
continued increase in canine seroprevalence during the past
decade.2,17,18 One major factor contributing to increasing rates of
VL is immunosuppression; modern treatment modalities for
malignant, autoimmune, and hereditary diseases, including
chemotherapy, biological agents,19 corticosteroids, radiation
therapy, and haematopoietic stem cell and solid organ transplan-
tation, as well as HIV infection, have greatly increased the numbers
of immunocompromised patients, who are vulnerable to VL. In this
Table 2
Clinical and laboratory characteristics of the 67 patients with visceral leishmaniasis according to their immune status (immunocompetent vs. immunocompromised)
Characteristic Immunocompetent
(n = 50)
Immunocompromised
(n = 17)
p-Value
Clinical symptoms
Fever 31 (62) 12 (71) NS
Weakness 28 (56) 10 (59) NS
Sweats 21 (42) 4 (23) NS
Rigors 12 (24) 3 (18) NS
Loss of weight 10 (20) 4 (24) NS
Cough 8 (16) 1 (6) NS
Abdominal pain 6 (12) 2 (12) NS
Rash 6 (12) 1 (6) NS
Headache 6 (12) 1 (6) NS
Physical ﬁndings
Splenomegaly 29 (58) 10 (59) NS
Hepatomegaly 24 (48) 9 (53) NS
Lymphadenopathy 17 (34) 7 (41) NS
Laboratory ﬁndings
Elevated inﬂammation markersa 42 (84) 12 (71) NS
Complete blood count
Anaemia 36 (72) 13 (76) NS
Thrombocytopenia 20 (40) 9 (53) NS
Leukopenia 23 (46) 4 (24) NS
Pancytopenia 16 (32) 7 (41) NS
Polyclonal hyperglobulinemia 29 (58) 11 (65) NS
Elevated transaminases 20 (40) 8 (47) NS
Low serum albumin 19 (38) 6 (35) NS
Microscopic haematuria 12 (24) 6 (35) NS
Positive non-organ speciﬁc autoantibodies 13 (26) 2 (12) NS
Treatment response 46 (94) 13 (86) NS
NS, non-signiﬁcant.
a Increased C-reactive protein and/or erythrocyte sedimentation rate.
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Hellenic Centre for Disease Control and Prevention from 2004 to
2013.20 Nevertheless, it should be pointed out that this number
may not be accurate, as infectious diseases are generally under-
reported in Greece.5
In this large cohort study it was found that the clinical features
of VL vary widely from asymptomatic to full-blown disease
characterized by fever, organomegaly, hypergammaglobulinemia,
and peripheral blood cytopenias.1,10,11 An atypical clinical
presentation is very challenging for clinicians as it can lead to a
considerable delay in the ﬁnal diagnosis. The absence of fever in VL
is rarely described in immunocompetent patients, but it usually
occurs in terms of HIV infection or drug-related immunosuppres-
sion.21 Indeed, 11 patients (16%) in the present series did not report
fever, of whom the majority (73%) were immunocompromised.
VL is also a not uncommon and important cause of reactive HS and
should be considered seriously in patients coming from endemic
areas.22 Four patients (6%) in the present study developed HS due to
VL. A high clinical suspicion, as well as the use of modern, high-yield
diagnostic tools such as PCR, may lead to the early diagnosis of
VL-associated HS, minimizing unnecessary  hospitalization and
potentially harmful investigations and treatments for HS.22,23
Bacterial co-infections were frequent (22%) in the study cohort,
including ﬁve patients (7.5%) with a second zoonosis (brucellosis
or Q-fever), which is not widely reported in the literature. The
extensive overlap in geographical distribution of many zoonoses,
close environments and climates, and animal migration may
contribute to this phenomenon.24 Advanced VL, especially in the
context of secondary neutropenia, is often complicated by bacterial
infections that are a major cause of mortality during hospitaliza-
tions.25 Indeed, high rates of co-infection (41–60%) have already
been reported in previous studies, with urinary infections being
the most common, followed by blood, respiratory, gastrointestinal,
and skin infections.26,27
Of interest, VL is associated with the development of several
non-organ speciﬁc autoantibodies (22% in the present studypopulation).10,28,29 These markers, together with other laboratory
immune ﬁndings, such as polyclonal hypergammaglobulinemia
and low serum complement levels, can be present without any
other profound clinical manifestation of autoimmune disease.28–31
The true clinical signiﬁcance of autoimmune serological ﬁndings is
condensed in the diagnostic dilemmas or treatment failures that
they can engender. Several patients with VL were initially treated
with corticosteroids or cyclophosphamide as they were misdiag-
nosed with autoimmune hepatitis or systemic lupus erythemato-
sus.29,31 Therefore, apart from the diagnostic dilemmas, a high
level of clinician vigilance is required, especially in areas endemic
for VL, before deciding to administer immunosuppression.29,30
Finally, regarding treatment, agents with efﬁcacy against VL
include amphotericin B, pentavalent antimonial drugs, paromo-
mycin (a parenteral aminoglycoside), and miltefosine (the ﬁrst oral
drug for the treatment of VL).1,2,10 Nevertheless, L-AMB is the drug
with the highest therapeutic efﬁcacy and the most favourable
safety proﬁle.10,32 Conventional amphotericin B also has a high
efﬁcacy and is actually the drug of choice in resource-limited
countries, e.g., India, although it is associated with a higher risk of
renal toxicity and other side effects. In this study L-AMB was
administered as the ﬁrst-line drug, similarly to many other
Mediterranean countries,33 with an initial treatment response of
approximately 90%. In addition, all of the patients who did not
respond or relapsed were eventually cured after the administration
of a second cycle of L-AMB. The incidence of adverse events was
relatively low and in most cases these were non-serious.10,34
Interestingly, one patient developed drug-related myocarditis35
and another developed a subclinical tumour lysis-like syndrome,
and these have rarely been reported as side effects in patients with
VL.36 In contrast, one of the three patients who were consequently
treated with pentamidine developed renal function deterioration
and irreversible insulin-dependent diabetes mellitus due to
pancreatic toxicity, which are both very well-described adverse
events.37,38 Pentamidine isethionate was the ﬁrst drug tried as
second-line treatment. It was used widely by district hospitals in
S.P. Georgiadou et al. / International Journal of Infectious Diseases 34 (2015) 46–5050areas endemic for kala-azar in India until the last decade. However,
due to its diminishing efﬁcacy (80%) over a period of time and
serious toxicity, its use has been limited.39
Treatment failure and relapse rates are particularly high in cases
of impaired cellular immunity, especially in HIV co-infection.40 The
usual strategy in these cases is to re-treat with L-AMB, as the
parasite does not necessarily develop resistance to this drug even
after repeated treatments or prophylactic use.10,41 Secondary
prophylaxis reduces the rate of recurrences, although optimal
regimens and the duration of prophylaxis have not yet been
deﬁned.10,42,43 In this study, the patient who relapsed despite
secondary prophylaxis was HIV-negative but profoundly immuno-
suppressed due to an underlying active haematological malignancy.
Moreover, it is well-known that VL is nearly always lethal without
treatment.1,10 Even with treatment, fatality rates can be 10% or
higher due to far-advanced disease, an underlying illness, or drug-
related toxicity. In this study cohort, the 6-month mortality rate was
9%, and although mortality could not be directly attributed to VL,
this probably reﬂects the frailty of the host immune status.
In conclusion, the diagnosis of VL remains challenging as the
disease is characterized by diverse and many atypical manifesta-
tions. Molecular methods contribute signiﬁcantly to a prompt and
timely diagnosis of VL, which is essential to reduce the marked
morbidity and mortality that this disease still carries. Indeed, early
recognition of special clinical and laboratory characteristics of VL
appears critical for the effective management of affected patients,
as the overall treatment efﬁcacy of L-AMB is very good.
Conﬂict of interest: All authors have nothing to declare.
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